{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:25:04Z","timestamp":1786922704064,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":95,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05956-w","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:43:04Z","timestamp":1778737384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of SGLT2 \u0131nhibitors on nutritional and \u0131mmunologic status in chronic heart failure"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-5999","authenticated-orcid":false,"given":"Meltem","family":"Alt\u0131nsoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadime","family":"Bozduman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fatay","family":"Tunca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enes","family":"\u00dc\u00e7g\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"18","key":"5956_CR1","first-page":"e876","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876\u201394.","journal-title":"Circulation"},{"key":"5956_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ahj.2024.02.006","volume":"270","author":"HJ Heerspink","year":"2024","unstructured":"Heerspink HJ, Provenzano M, Vart P, Jongs N, Correa-Rotter R, Rossing P, et al. Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. Am Heart J. 2024;270:125\u201335.","journal-title":"Am Heart J"},{"issue":"3","key":"5956_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/jcsm.12086","volume":"7","author":"T Sente","year":"2016","unstructured":"Sente T, Van Berendoncks AM, Hoymans VY, Vrints CJ. Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle. 2016;7(3):261\u201374.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"5956_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ejhf.240","volume":"17","author":"P Rossignol","year":"2015","unstructured":"Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail. 2015;17(4):424\u201333.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"5956_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s13539-012-0089-z","volume":"3","author":"S von Haehling","year":"2012","unstructured":"von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle. 2012;3(4):213\u20137.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"5956_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/1076029617703482","volume":"24","author":"MI Hayiroglu","year":"2018","unstructured":"Hayiroglu MI, Keskin M, Keskin T, Uzun AO, Altay S, Kaya A, et al. A Novel Independent Survival Predictor in Pulmonary Embolism: Prognostic Nutritional Index. Clin Appl Thromb Hemost. 2018;24(4):633\u20139.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"5956_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.numecd.2017.01.005","volume":"27","author":"M Keskin","year":"2017","unstructured":"Keskin M, Hayiroglu MI, Keskin T, Kaya A, Tatlisu MA, Altay S, et al. A novel and useful predictive indicator of prognosis in ST-segment elevation myocardial infarction, the prognostic nutritional index. Nutr Metab Cardiovasc Dis. 2017;27(5):438\u201346.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"5956_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jjcc.2013.05.007","volume":"62","author":"T Narumi","year":"2013","unstructured":"Narumi T, Arimoto T, Funayama A, Kadowaki S, Otaki Y, Nishiyama S, et al. Prognostic importance of objective nutritional indexes in patients with chronic heart failure. J Cardiol. 2013;62(5):307\u201313.","journal-title":"J Cardiol"},{"issue":"2","key":"5956_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jjcc.2018.01.012","volume":"72","author":"H Wada","year":"2018","unstructured":"Wada H, Dohi T, Miyauchi K, Jun S, Endo H, Doi S, et al. Relationship between the prognostic nutritional index and long-term clinical outcomes in patients with stable coronary artery disease. J Cardiol. 2018;72(2):155\u201361.","journal-title":"J Cardiol"},{"issue":"36","key":"5956_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"3","key":"5956_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352\u201380.","journal-title":"Eur J Heart Fail"},{"issue":"10254","key":"5956_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"12","key":"5956_CR13","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.amjcard.2005.02.022","volume":"95","author":"KV Huehnergarth","year":"2005","unstructured":"Huehnergarth KV, Mozaffarian D, Sullivan MD, Crane BA, Wilkinson CW, Lawler RL, et al. Usefulness of relative lymphocyte count as an independent predictor of death\/urgent transplant in heart failure. Am J Cardiol. 2005;95(12):1492\u20135.","journal-title":"Am J Cardiol"},{"issue":"1","key":"5956_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13098-024-01409-6","volume":"16","author":"Y Peng","year":"2024","unstructured":"Peng Y, Lin A, Luo B, Chen L, Lin Y. The effect of prognostic nutritional index on diabetic patients with myocardial infarction. Diabetol Metab Syndr. 2024;16(1):179.","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"5956_CR15","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.amjcard.2011.06.020","volume":"108","author":"P Gastelurrutia","year":"2011","unstructured":"Gastelurrutia P, Lupon J, Domingo M, Ribas N, Noguero M, Martinez C, et al. Usefulness of body mass index to characterize nutritional status in patients with heart failure. Am J Cardiol. 2011;108(8):1166\u201370.","journal-title":"Am J Cardiol"},{"issue":"3","key":"5956_CR16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"5956_CR17","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"16","key":"5956_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"21","key":"5956_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"10","key":"5956_CR20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"1","key":"5956_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97(1):202\u201312.","journal-title":"Kidney Int"},{"issue":"3","key":"5956_CR22","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jtcvs.2021.03.073","volume":"164","author":"VA Ferraris","year":"2022","unstructured":"Ferraris VA. Commentary: benefits of SGLT2 inhibition in heart failure: a bellwether for importance of other metabolic pathways. J Thorac Cardiovasc Surg. 2022;164(3):900\u20131.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"5956_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejim.2023.04.002","volume":"114","author":"G Fan","year":"2023","unstructured":"Fan G, Guo DL. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: a meta-analysis of randomized controlled trials. Eur J Intern Med. 2023;114:49\u201357.","journal-title":"Eur J Intern Med"},{"key":"5956_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106243","volume":"180","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Antonopoulos AS, Katsimichas T, Oikonomou E, Siasos G, Aggeli C, et al. The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis. Pharmacol Res. 2022;180:106243.","journal-title":"Pharmacol Res"},{"key":"5956_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.777083","volume":"12","author":"C Sardu","year":"2021","unstructured":"Sardu C, Massetti M, Testa N, Martino LD, Castellano G, Turriziani F, et al. Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. Front Pharmacol. 2021;12:777083.","journal-title":"Front Pharmacol"},{"key":"5956_CR26","doi-asserted-by":"publisher","first-page":"1012220","DOI":"10.3389\/fcvm.2022.1012220","volume":"9","author":"A Cesaro","year":"2022","unstructured":"Cesaro A, Gragnano F, Paolisso P, Bergamaschi L, Gallinoro E, Sardu C, et al. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study. Front Cardiovasc Med. 2022;9:1012220.","journal-title":"Front Cardiovasc Med"},{"key":"5956_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107759","volume":"216","author":"C Sardu","year":"2025","unstructured":"Sardu C, Trotta MC, Marfella LV, D\u2019Amico G, La Marca C, Mauro C, et al. Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator. Pharmacol Res. 2025;216:107759.","journal-title":"Pharmacol Res"},{"key":"5956_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112452","volume":"228","author":"C Sardu","year":"2025","unstructured":"Sardu C, Marfella LV, Rinaldi L, Sasso FC, Cozzolino D, Nappo F, et al. Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study. Diabetes Res Clin Pract. 2025;228:112452.","journal-title":"Diabetes Res Clin Pract"},{"key":"5956_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155243","volume":"137","author":"C Sardu","year":"2022","unstructured":"Sardu C, Massimo Massetti M, Rambaldi P, Gatta G, Cappabianca S, Sasso FC, et al. SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study. Metabolism. 2022;137:155243.","journal-title":"Metabolism"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05956-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:42:33Z","timestamp":1786920153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05956-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5956"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05956-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Due to the retrospective design and anonymized data collection, the requirement for written informed consent was waived by the local Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"702"}}